Skip to main content

Advertisement

Figure 4 | Molecular Neurodegeneration

Figure 4

From: Expression profiling in APP23 mouse brain: inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment

Figure 4

LXR agonists down-regulate expression of pro-inflammatory genes in microglia and astrocytes. Microglial cell line BV2 and astrocytes established from wild type (wt) and LXRdko (dko) mice were pre-treated with LXR ligand GW or vehicle for 18 h prior to LPS treatment (50 ng/ml). Control cells received vehicle only (veh). For GW treated cells (LPS+GW) the ligand was co-applied with LPS. Cells were harvested 24 hours after LPS administration and the mRNA expression measured by RT-QPCR. A: BV-2 cells. Values are fold of vehicle. *, p < 0.05 LPS+GW treated compared to LPS only treated cells. B and C: WT and dko astrocytes were treated with LPS and GW as in A and mRNA expression of iNOS (B) and IL-6 (C) measured by RT-QPCR. Values (means ± SEM) are fold of wild type, vehicle treated cells of at least two independent experiments. Note that unlike in WT cells, GW does not decrease the expression of iNOS and IL-6 in dko cells. (LPS+GW in dko versus LPS+GW in WT, p < 0.01). For all experiments, LXR ligands were applied at 5 μM concentration. Statistics were performed by two-tailed Student's t test.

Back to article page